Weedstocks Newswire Feed
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES/
VANCOUVER, Sept. 26, 2018 /CNW/ - Koios Beverage Corp. (CSE:KBEV)(OTC: KBEVF) (the "Company" or "Koios") is pleased to announce that the world's first cannabis infused nootropic beverage is scheduled for release in November.
The new product will be a collaboration with the Company's partner Keef Brands, a division of CanCore Concepts Inc. (CanCore), and Koios' wholly owned subsidiary Cannavated Beverage Corp. Cannavated was formed specifically to license the nootropic formulas to other companies working in the area of cannabis-infused beverages.
Keef Brands will manufacture, market and sell a line of beverages that are not only infused with THC, but also contain the nootropic supplements from the Koios line of brain enhancing functional beverages. The resulting product will be the first in the world to combine cannabis infusion with nootropic supplements that enhance the consumer's mental acuity.
Keef Brands has the exclusive rights to the Cannavated nootropic formula for Colorado, with the option of expanding the licensing agreement throughout the U.S., provided it complies with all rules and regulations in the markets where cannabis has been made legal.
TORONTO, Sept. 26, 2018 /CNW/ - The Supreme Cannabis Company, Inc. ("Supreme Cannabis" or the "Company") (TSXV: FIRE) (OTCQX: SPRWF) (FRA: 53S1), announced that the Company's wholly owned subsidiary, 7ACRES, has entered into a supply agreement to provide dried cannabis to Tilray Canada Ltd., a subsidiary of Tilray Inc.® (NASDAQ: TLRY), a global leader in cannabis research, cultivation, processing and distribution currently serving tens of thousands of patients in 12 countries spanning 5 continents.
This agreement is a guaranteed commitment to purchase. It will cover the twelve-month period starting October 1, 2018 and is estimated to have a value of approximately C$12 million. As was the case with the recently announced deal between the two companies, the dried cannabis provided to Tilray by 7ACRES will be used primarily to support medical cannabis patients in Canada, including Tilray's robust patient population.
"We are excited to be entering into this agreement with Tilray, an organization – like Supreme Cannabis – that focuses on the end user and demands leading quality assurance standards," said John Fowler, President of The Supreme Cannabis Company. "Tilray has built an industry-leading global medical distribution platform, which has resulted in robust demand for high quality cannabis products. We are happy to provide 7ACRES premium products alongside Tilray's well-regarded and existing lineup to support medical patients around the world."
About Supreme Cannabis
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
LONDON, ON, Sept. 26, 2018 /CNW/ - INDIVA Limited (the "Company" or "INDIVA") (TSX-V:NDVA) congratulates Pete Young on the Amazon and Indigo listing of his soon to be released memoir, The High Road: a Pot Grower's Journey from the Black Market to the Stock Market. The High Road tells the story of Pete's activism and efforts to legalize cannabis in Canada and compassionate supply of cannabis to medical clients through the London Compassion Society, a not-for-profit he founded.
"Pete worked very hard on this project. The book's listing on Amazon and Indigo is validation for his good work." explained Niel Marotta, the Company's CEO. "We couldn't be more proud of Pete."
The High Road is being published and will be available for purchase on October 17, 2018, which corresponds with the legalization of cannabis in Canada.
About INDIVA INDIVA's wholly owned subsidiary is a Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulation ("ACMPR").
Khiron Life Sciences Director and Former President of Mexico, Mr. Vicente Fox to Present Keynote Address at Global Cannabis Business Conference in Jamaica
Conference to offer insight on global medicinal, health, regulatory, business and investment landscape
TORONTO, Sept. 26, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN, OTCQB: KHRNF, Frankfurt: A2JMZC), a Canadian integrated medical cannabis company with its core operations in Colombia, announced that former President of Mexico and Khiron Board member Mr. Vicente Fox will present a keynote address at CanEx Jamaica Business Conference & Expo on September 28th in Montego Bay, Jamaica, where he will discuss his views on the medical cannabis industry in Mexico and Latin America.
Mr. Fox stated, "The cannabis industry offers tremendous economic health and social benefits in Mexico and around the world. I welcome the opportunity to share, network and advocate for its continued progress at CanEx Jamaica." From December 2000 to November 2006, Mr. Fox was the 55th President of Mexico. Prior to that, he was the Chief Executive Officer of Coca Cola Latin America.
Mr. Alvaro Torres, Khiron Co-founder and CEO stated: "We congratulate Mr. Fox on this invitation to present at CanEx Jamaica. As an important global cannabis conference his active participation articulates and reinforces Khiron´s vision of becoming the leading medical cannabis company across Latin America."
The CanEx Jamaica Business Conference and Expo is an annual business-to-business event that brings together top cannabis industry experts from the U.S., Canada, South and Central America, Europe, Australia and the Caribbean. For further detail visit www.canexjamaica.com
TrackLoop Analytics Announces Acquisition of Cannabis, Food and Pharma Logistics Tracking Technology
Entering $250B Food Logistics Market With End-to-end Solution
VANCOUVER, Sept. 26, 2018 /CNW/ - TrackLoop Analytics Corp. (the "Company" or "TrackLoop") (CSE: TOOL) (FWB: B2IN) an analytics software company, is pleased to announce the acquisition of ChainTrack Technologies Inc. ("ChainTrack"), a company providing Internet-of-Things (IoT) powered supply chain tracking solutions, including "cold chain" (refrigerated supply chain) tracking, for the food and pharmaceutical industries.
On September 25, 2018 (the "Closing Date"), the Company completed the transaction pursuant to a share exchange agreement made effective as of September 25, 2018 (the "Acquisition Agreement") among the Company, ChainTrack and the shareholders of ChainTrack (the "Selling Shareholders"), whereby the Company acquired 100% of the common shares of ChainTrack from the Selling Shareholders, by issuing 16,500,000 common shares of the Company (the "Consideration Shares") to the Selling Shareholders on a pro-rata basis, following the completion of which, ChainTrack is now a wholly-owned subsidiary of the Company.
The Consideration Shares are subject to resale restrictions, with 20% released on the Closing Date and 20% released every three months thereafter.
Announcement of Private Placement
Brand developed in response to priorities and requests for quality value products from retail partners across the country
MONCTON, NB, Sept. 26, 2018 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of medical marijuana, today unveiled Trailblazer, the newest addition to their portfolio of products ready for the launch of the adult use recreational cannabis market in Canada.
Trailblazer was developed in rapid response to ongoing discussions with Organigram's jurisdictional and retail partners across Canada and their focus on offering high value offerings. "Our brand strategy is creative and thoughtful, based on a concerted effort to wholly understand our current and future customers," explains Ray Gracewood, Chief Commercial Officer, Organigram.
"We always want to be nimble enough to respond to what our partners need. Across the country, the message has been clear that a high value, quality product is an important consideration for customers and an effective tool to help combat the black market for cannabis. Trailblazer delivers on both those fronts."
The brand concept behind Trailblazer is a celebration of the end of prohibition, Gracewood says.
Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease
SWINDON, U.K., and LAS VEGAS, Sept. 26, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences' proprietary active pharmaceutical ingredients ("APIs") for its Parkinson's disease therapies. A proof of concept study will be conducted by Catalent at its Swindon, U.K. facility to evaluate GB Sciences' clinical candidates GBS101, GBS102, and GBS103 using Catalent's proprietary Zydis® Orally Disintegrating Tablet (ODT) technology.
GB Sciences' three patent-pending APIs for Parkinson's disease are complex mixtures containing up to nine individual components that function synergistically. Preclinical studies have shown that these cannabinoid-containing complex mixtures are more potent than would have been predicted by combining the activity of each individual compound.
"To prepare our Parkinson's disease formulations for human clinical trials, we wanted the ease-of-use offered by Zydis ODTs for our Parkinson's patients, many of whom may have difficulties in swallowing. Catalent's proprietary delivery method also potentially offers consistent dosing for our complex cannabinoid- and terpenoid-containing APIs," explained Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "The creation of GB Sciences' proprietary APIs in Zydis ODT formulations is a very important step towards readying them for our Exploratory IND filing and planned phase zero human trial for patients with mild to moderate Parkinson's disease."
Jonathan Arnold, President of Oral Drug Delivery at Catalent, added, "Dissolving rapidly in the mouth, ODTs are convenient and ease administration, offering an alternate dosage form for patients who have difficulty swallowing, as is sometimes the case with Parkinson's disease, as well as with geriatric or pediatric patients."
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) announced that the board of directors of the Company has approved the granting of 350,000 incentive stock options (the “Options”) to certain officers of the Company. The Options are exercisable at a price of $1.60 per share for a period of five years and are subject to vesting as to one-third the number of Options granted on each of September 25, 2019, 2020 and 2021.
About Emblem Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations. Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the ultimate parent company of GrowWise Health Ltd., one of Canada’s leading medical cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange. For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
Morgan Cates H+K Strategies 416.413.4649 email@example.com
For other inquiries, please contact: Ethan Karayannopoulos Investor Relations Emblem Corp. 647.748.9696 firstname.lastname@example.org
OTTAWA, Sept. 25, 2018 /CNW/ - CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) ("CannaRoyalty" or the "Company"), a leading North American cannabis products and brands company, announced today that the Company's Chairman and CEO, Marc Lustig will be presenting at Cannabis Invest, one of Europe's leading cannabis investment conferences.
The Cannabis Invest conferences are attended by professional investors, policymakers, cannabis industry stakeholders and senior management of the world's leading cannabis companies. Mr. Lustig will present at the events in London on October 2, 2018 at the May Fair Hotel from 9:25am to 9:45am BST and in Geneva on October 3, 2018 at the Mandarin Oriental Hotel from 9:25am to 9:45am CEST.
CannaRoyalty is a North American cannabis consumer product company currently focused on building a leading distribution business in California, the world's largest regulated cannabis market. By building a world-class logistics platform and supporting contract manufacturing assets, the Company intends to support the growth of new and established cannabis brands. The Company believes California, home to some of the world's most discerning consumers and a nexus of information and trends, will be the point of inception for the global cannabis brands of the future. CannaRoyalty has developed a diversified portfolio of assets within the cannabis sector, including research, infrastructure and intellectual property to support our existing brands, partner products and distribution networks. The Company's leadership and staff combines passion and a hands-on understanding of the cannabis industry, with proven financial and legal expertise. CannaRoyalty's Common Shares trade on the Canadian Stock Exchange (CSE) under the symbol CRZ and in the US on the OTCQX under the symbol CNNRF.
GATINEAU, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) is pleased to announce that it has shipped its first order for the Canadian adult-use cannabis market.
The shipment is yet another example of the Company executing its commitment to shareholders and consumers to supply innovative and easy-to-use products, powered by HEXO, across Canada.
“This is a historic moment for HEXO,” said Sonia Isabel, Vice-President of Sales for HEXO. “We are so proud of all of our teams for the hard work that they have put in leading up to this moment, but it doesn’t stop now. We look forward to continuing to provide high-quality products and client experiences as we continue our expansion throughout Canada and beyond.”
HEXO has a five-year, $1 billion contract as the preferred supplier to the Société québécoise du cannabis (Quebec) in addition to securing the online distribution contract for the province. HEXO has also made agreements to supply adult-use cannabis in Ontario, and British Columbia. Finally, The Company has secured a large stake in Fire & Flower, a leading adult-use retail cannabis store that is poised to capture a significant portion of the Canadian market and expects to serve all market segments in Canada in the near future.
About HEXO Corp.